American Shared Hospital Services: directors' dealings · United States · SEC (Form 4)

About American Shared Hospital Services

American Shared Hospital Services (ticker: AMS) is a U.S.-listed healthcare company trading on NYSE American in the United States. It occupies a specialized niche in advanced radiation oncology and stereotactic radiosurgery, with a business model built around turnkey technology solutions rather than broad hospital operations. Founded in 1980 and headquartered in San Francisco, California, the company has long focused on providing highly specialized, capital-intensive cancer treatment infrastructure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/744825/000143774926010731/asha20251231_10k.htm?utm_source=openai)) AMS operates through two reportable segments: medical equipment leasing and direct patient services. In its leasing business, the company places Gamma Knife systems and related radiotherapy equipment at hospitals, typically under fee-per-use or revenue-sharing arrangements. This segment is tied to procedure volumes, reimbursement dynamics, and equipment utilization. In direct patient services, AMS owns and operates treatment facilities where patients receive care directly at company-run sites. The latest SEC filings show that AMS provides Gamma Knife services to several U.S. medical centers through an indirect interest in GK Financing, LLC, and also operates facilities in Lima, Peru; Guayaquil, Ecuador; and Puebla, Mexico, alongside three radiation therapy sites in Rhode Island acquired in 2024. ([sec.gov](https://www.sec.gov/Archives/edgar/data/744825/000143774926010731/asha20251231_10k.htm?utm_source=openai)) From a competitive standpoint, AMS is best described as a niche infrastructure and services provider in a complex segment of oncology care. Its differentiation comes from combining financing, deployment, and operation of specialized radiosurgery systems that are difficult to replicate and require deep technical and commercial expertise. The company’s long-standing relationship with Elekta, the manufacturer of the Gamma Knife platform, supports its credibility in a market where equipment quality, service reliability, and clinical outcomes matter materially. Rather than competing with large diversified healthcare groups, AMS competes in a narrower field defined by hospital partnerships, treatment center economics, and access to advanced radiation therapy technology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/744825/000143774926010731/asha20251231_10k.htm?utm_source=openai)) Recent developments suggest a gradual shift in the company’s mix toward direct patient services and a broader radiation therapy footprint. The 2025 annual filing indicates that direct patient services became more important, while Gamma Knife activity in some markets was affected by equipment upgrades, including downtime in Peru tied to a system modernization. The company also continued to build out its Rhode Island platform following the 2024 acquisition, which expanded its direct-care presence. For investors, AMS remains a small-cap healthcare name with potentially attractive growth optionality, but also with meaningful execution, funding, and operational risks typical of a specialized provider on NYSE American in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/744825/000143774926010731/asha20251231_10k.htm?utm_source=openai))